Hepatic farnesoid X-receptor isoforms α2 and α4 differentially modulate bile salt and lipoprotein metabolism in mice

PLoS One. 2014 Dec 15;9(12):e115028. doi: 10.1371/journal.pone.0115028. eCollection 2014.

Abstract

The nuclear receptor FXR acts as an intracellular bile salt sensor that regulates synthesis and transport of bile salts within their enterohepatic circulation. In addition, FXR is involved in control of a variety of crucial metabolic pathways. Four FXR splice variants are known, i.e. FXRα1-4. Although these isoforms show differences in spatial and temporal expression patterns as well as in transcriptional activity, the physiological relevance hereof has remained elusive. We have evaluated specific roles of hepatic FXRα2 and FXRα4 by stably expressing these isoforms using liver-specific self-complementary adeno-associated viral vectors in total body FXR knock-out mice. The hepatic gene expression profile of the FXR knock-out mice was largely normalized by both isoforms. Yet, differential effects were also apparent; FXRα2 was more effective in reducing elevated HDL levels and transrepressed hepatic expression of Cyp8b1, the regulator of cholate synthesis. The latter coincided with a switch in hydrophobicity of the bile salt pool. Furthermore, FXRα2-transduction caused an increased neutral sterol excretion compared to FXRα4 without affecting intestinal cholesterol absorption. Our data show, for the first time, that hepatic FXRα2 and FXRα4 differentially modulate bile salt and lipoprotein metabolism in mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bile Acids and Salts / metabolism*
  • Lipid Metabolism
  • Lipoproteins / metabolism*
  • Liver / metabolism*
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Protein Isoforms / genetics
  • Protein Isoforms / metabolism
  • Receptors, Cytoplasmic and Nuclear / genetics
  • Receptors, Cytoplasmic and Nuclear / metabolism*

Substances

  • Bile Acids and Salts
  • Lipoproteins
  • Protein Isoforms
  • Receptors, Cytoplasmic and Nuclear
  • farnesoid X-activated receptor

Grants and funding

Supported within the framework of Top Institute Pharma, The Netherlands, project T2-110. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.